Memorial Sloan-Kettering Cancer Center experience with paclitaxel in the treatment of breast cancer: From advanced disease to adjuvant therapy Conference Paper
| Authors: | Seidman, A. D.; Hudis, C. A.; Norton, L. |
| Title: | Memorial Sloan-Kettering Cancer Center experience with paclitaxel in the treatment of breast cancer: From advanced disease to adjuvant therapy |
| Conference Title: | Innovative Approaches to Breast Cancer Treatment: The Role of Paclitaxel |
| Abstract: | The novel chemotherapeutic agent paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has received more attention than perhaps any ether drug in the past two decades in its development for the treatment of breast cancer. Its unique mechanism of action, demonstrated safety profile, and significant antitumor activity in thousands of patients treated in clinical trials thus far have led to recent US Food and Drug Administration approval of its use against chemotherapy-refractory metastatic breast cancer. This report will summarize the series of clinical investigations with paclitaxel in patients with metastatic breast cancer that have been completed over the past 3 years at Memorial Sloan-Kettering Cancer Center and address present and future avenues of research. |
| Keywords: | cancer survival; survival rate; clinical trial; fatigue; cisplatin; doxorubicin; advanced cancer; conference paper; paclitaxel; cancer adjuvant therapy; chemotherapy, adjuvant; cancer staging; lymph node metastasis; lymphatic metastasis; quality of life; phase 2 clinical trial; breast cancer; bone marrow suppression; mastectomy; stomatitis; antineoplastic combined chemotherapy protocols; epidermal growth factor receptor; cyclophosphamide; bone pain; breast neoplasms; docetaxel; monoclonal antibody; neoplasm metastasis; remission induction; cancer care facilities; new york city; phase 3 clinical trial; phase 1 clinical trial; anthracycline; infusions, intravenous; granulocyte colony stimulating factor; granulocyte colony-stimulating factor; intravenous drug administration; receptor antibody; growth factor receptor; edatrexate; subcutaneous drug administration; human; female; priority journal |
| Journal Title | Seminars in Oncology |
| Volume: | 22 |
| Issue: | 4 Suppl. 8 |
| Conference Dates: | 1994 May 9 |
| Conference Location: | Rio de Janeiro, Brazil |
| ISBN: | 0093-7754 |
| Publisher: | Elsevier Inc. |
| Date Published: | 1995-08-01 |
| Start Page: | 3 |
| End Page: | 8 |
| Language: | English |
| PUBMED: | 7543701 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Conference Paper -- Export Date: 28 August 2018 -- Source: Scopus |
Citation Impact
Related MSK Work